文献类型：期刊文献

英文题名：Research progress of bioactive compounds of Traditional Chinese medicine in the treatment of myocardial fibrosis-related signaling pathways

作者：Li, Qianrong[1,2,3];Liu, Ai[1,2,3];Ren, Chunzhen[1,2,3];Zhi, Xiaodong[1,2,3,4];Wang, Xuehan[2,3,5];Lu, Weijie[1,2,3];Guo, Xiaoying[1,2,3];Li, Linchan[1,2,3,6];Zhao, Xinke[1,2,3,4];Li, Yingdong[1,2,3]

第一作者：Li, Qianrong

通信作者：Zhao, XK[1];Li, YD[1];Zhao, XK[2]

机构：[1]Gansu Univ Chinese Med, Sch Tradit Chinese & Western Med, Lanzhou 730000, Peoples R China;[2]Gansu Prov Key Lab Chinese Med Prevent & Treatment, Lanzhou 730000, Peoples R China;[3]Natl Adm Tradit Chinese Med, Key Clin Specialty Natl Hlth Commiss Peoples Repu, Key Specialized Cardiovasc Lab, Lanzhou 730000, Peoples R China;[4]Gansu Univ Chinese Med, Affiliated Hosp, Lanzhou 730000, Peoples R China;[5]Lanzhou Univ, Clin Med Coll 1, Lanzhou 730000, Peoples R China;[6]Shanxi Provincal Hosp Chinese Med, Xian 710000, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Univ Chinese Med, Sch Tradit Chinese & Western Med, Lanzhou 730000, Peoples R China;[2]corresponding author), Gansu Univ Chinese Med, 35 Dingxi East Rd, Lanzhou 730000, Gansu, Peoples R China.|[10735]甘肃中医药大学;

年份：2026

卷号：355

外文期刊名：JOURNAL OF ETHNOPHARMACOLOGY

收录：;WOS:【SCI-EXPANDED(收录号:WOS:001598107900001)】；

基金：This work was supported by the Gansu Jiaoyu Jiebang Guashuai Project (No. 2021 jyjbgs-03) , National Natural Science Foundation of China (NO. 82360926,82374279) ,Gansu Province Dual Top-class Scientific Research Key Project (GSSYLXM-05) ,Gansu Provincial Science and Technology Major Project (NO. 20ZD7FA002) ,Gansu Provincial University Teachers ' Innovation Fund Project in 2025 (No.2025B-126) ,2024 Gansu Province Outstanding Doctoral Project (24JRRA569) .

语种：英文

外文关键词：Traditional Chinese medicine; Bioactive compounds; Myocardial fibrosis; Signal pathway; Action mechanism; Cardiac fibroblasts

摘要：Ethnopharmacological relevance: Myocardial fibrosis (MF),characterized by excessive extracellular matrix (ECM) remodeling, represents a central pathological process in progressive cardiovascular diseases and drives cardiac functional impairment.Contemporary anti-fibrotic therapies face limitations due to inadequate target specificity and systemic toxicity, whereas bioactive compounds derived from traditional Chinese medicine (TCM) offer novel multi-target therapeutic strategies for MF reversal. Aim of the study: This review synthesizes evidence on molecular mechanisms by which TCM compounds modulate fibrotic signaling networks, providing translational insights for precision anti-fibrotic interventions. Materials and methods: Following PRISMA guidelines,we systematically searched major scientific databases (PubMed, Web of Science, Embase, Cochrane Library, CNKI) from January 2000 to September 2025 using predefined keywords: myocardial fibrosis, traditional Chinese medicine, bioactive compounds, and herbal pharma cology. Eligible experimental studies elucidating mechanistic pathways were analyzed to map chemical constituents, pharmacological actions, and pathway interactions. Results: TCM-derived compounds including tanshinone IIA and astragaloside IV demonstrate anti-MF efficacy by suppressing fibroblast activation and collagen deposition through coordinated modulation of TGF-beta 1/Smad, MAPK, and NF-kappa B pathways, correlating with reduced MF severity and improved cardiac function. Conclusion: TCM bioactives exhibit unique therapeutic potential by remodeling the fibrotic microenvironment through multi-modal signaling pathways, overcoming limitations of single-target approaches.Current constraints include insufficient validation in dynamic disease models and interspecies pharmacokinetic variability.Future research should prioritize integrating organ-on-a-chip systems with spatial metabolomics. To bridge current translational gaps, future studies must converge cutting-edge technologies: (1) Organ-on-a-chip platforms simulating human cardiac microenvironments; (2) Spatial metabolomics mapping compound distribution; and (3) AI-driven screening to construct predictive compound-pathway-phenotype networks. Such integration, aligned with ICH guidelines, could propel TCM from empirical practice to precision cardiology.